Evidence map›Paper›PMID 28863467›Full record

ArticleThe Journal of infectious diseases2017

Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.

Shashank Gupta, Laurene Cheung, Supriya Pokkali, Kathryn Winglee, Haidan Guo, John R Murphy, William R Bishai

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. The Research Progress in Immunotherapy of Tuberculosis.Frontiers in cellular and infection microbiology · 2021
    Review
  8. Review
  9. Review
  10. FX11 limitsDisease models & mechanisms · 2020
    Article
  11. Review
  12. Review
  13. MDSCs in infectious diseases: regulation, roles, and readjustment.Cancer immunology, immunotherapy : CII · 2019
    Review
  14. Article
  15. Review
  16. Review
  17. Proteomics ofFrontiers in immunology · 2018
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shashank GuptaCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
Laurene CheungCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
Supriya PokkaliCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
Kathryn WingleeCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
Haidan GuoCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
John R MurphyCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
William R BishaiCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
Johns Hopkins University · US

Funding

Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
Mycobacterium tuberculosis Survival Regulatory GenesR01AI037856 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BISHAI, WILLIAM RAMSES · 1997 to 2020
$7.2M
PK/PD Evaluation Resistance Development in Caseating GranulomaR01AI079590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BISHAI, WILLIAM RAMSES · 2008 to 2011
$2.5M
NIAID NIH HHS R01 AI037856NIAID NIH HHS R01 AI079590NIGMS NIH HHS T32 GM008752
6 · The paper itself

Abstract

Host-directed therapies that augment host immune effector mechanisms may serve as important adjunctive therapies for tuberculosis treatment. We evaluated the activity of denileukin diftitox in an acute mouse model of tuberculosis (TB) infection and analyzed the cellular composition and bacterial burden in lungs and spleens. These in vivo studies show that denileukin diftitox potentiates standard TB treatment in the mouse model, an effect which may be due to depletion of T-regulatory and myeloid-derived suppressor cells during TB infection. Our results indicate that denileukin diftitox and other suppressor cell-depleting therapies may be useful adjunctive, host-directed therapies for TB.

Indexed as

AnimalsDiphtheria ToxinDisease Models, AnimalHumansImmunotherapyInterleukin-2LungMiceMice, Inbred C57BLMycobacterium tuberculosisMyeloid-Derived Suppressor CellsRecombinant Fusion ProteinsRecombinant ProteinsSpleenT-Lymphocytes, RegulatoryTuberculosisdenileukin diftitoxDiphtheria ToxinInterleukin-2Recombinant Fusion ProteinsRecombinant ProteinsDenileukin diftitox recombinant fusion protein toxinHost-directed therapyImmunotherapyTuberculosis

Identifiers

PMID28863467
PMCPMC5853937
OpenAlexW2617628401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.